<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29677" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sulindac</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Munjal</surname>
            <given-names>Akul</given-names>
          </name>
          <aff>Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wadhwa</surname>
            <given-names>Roopma</given-names>
          </name>
          <aff>South Carolina Department of Mental Health</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Akul Munjal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Roopma Wadhwa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>15</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29677.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Sulindac is classified as a nonsteroidal anti-inflammatory drug (NSAID), exhibiting anti-inflammatory and analgesic properties. Similar to other NSAIDs, sulindac is primarily utilized for the treatment of conditions characterized by acute or chronic inflammation. However, according to the manufacturer, its indications are broad.&#x000a0;The medication is prescribed for the acute management of musculoskeletal shoulder pain, acute gouty arthritis, osteoarthritis resulting from wear and tear, and inflammatory arthritic conditions, including both rheumatoid arthritis and ankylosing spondylarthritis. Healthcare providers recommend administering the lowest effective dose tailored to each patient's needs for the initial treatment and the shortest duration possible. This activity provides an overview of the indications, contraindications, mechanism of action, adverse events, and essential components of sulindac therapy in clinical practice.&#x000a0;This activity enables healthcare professionals to tailor treatment plans, optimize dosage regimens, and minimize adverse reactions by enhancing their competence in&#x000a0;sulindac&#x000a0;pharmacology.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Implement evidence-based guidelines for the safe and effective use of sulindac in patients with inflammatory conditions.</p></list-item><list-item><p>Assess patient response to sulindac treatment, including monitoring for adverse reactions and efficacy.</p></list-item><list-item><p>Apply dosing adjustments based on individual patient factors such as age, comorbidities, and concurrent medications.</p></list-item><list-item><p>Collaborate with pharmacists and other healthcare professionals to improve outcomes and treatment efficacy for patients who benefit from sulindac.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29677&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29677">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29677.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Sulindac is classified as a nonsteroidal anti-inflammatory drug (NSAID), exhibiting anti-inflammatory and analgesic properties. Similar to other NSAIDs,&#x000a0;sulindac&#x000a0;is primarily utilized&#x000a0;for&#x000a0;the treatment of conditions&#x000a0;characterized by&#x000a0;acute or chronic inflammation. However,&#x000a0;according to the manufacturer, its indications are broad.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Sulindac is approved by the US Food and Drug Administration (FDA) for the conditions mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Sulindac is indicated for short-term use in the acute management of musculoskeletal shoulder pain, including acute subacromial bursitis and supraspinatus tendinitis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sulindac has FDA approval for various forms of arthritis, including osteoarthritis resulting from wear and tear and inflammatory arthritic conditions such as rheumatoid arthritis and ankylosing spondylarthritis.<xref ref-type="bibr" rid="article-29677.r1">[1]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sulindac is also approved for the treatment of acute gouty arthritis.<xref ref-type="bibr" rid="article-29677.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Familial adenomatous polyposis (FAP) is a condition characterized by pediatric adenomas in the lower gastrointestinal tract and frequently results in colonic adenocarcinomas. Numerous&#x000a0;studies have explored diverse chemopreventive strategies to curb the progression of colonic adenomas and the subsequent development of adenocarcinomas.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sulindac is one of the most extensively studied drugs in this chemopreventative strategy.<xref ref-type="bibr" rid="article-29677.r2">[2]</xref>&#x000a0;As per the American Society of Colon and Rectal Surgeons Clinical Practice Guidelines, individuals diagnosed with FAP, attenuated&#x000a0;FAP (AFAP), or MUTYH-associated polyposis who have a retained rectum or established duodenal adenomas should undergo an individualized risk/benefit assessment for chemoprevention.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The guidelines recommend considering either sulindac or celecoxib. Moreover, when prescribing sulindac, proton pump inhibitor coadministration is preferred.<xref ref-type="bibr" rid="article-29677.r3">[3]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29677.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Sulindac is a nonselective COX (cyclooxygenase) inhibitor that reversibly inhibits COX-1 and COX-2 enzymes. The COX pathway is one of the&#x000a0;2 main pathways in arachidonic acid metabolism (the other involves leukotriene synthesis). The COX pathway results in the synthesis of both prostaglandins and thromboxanes. These are both critical mediators of inflammation and platelet aggregation.<xref ref-type="bibr" rid="article-29677.r4">[4]</xref></p>
        <p>Prostaglandin E2 (PGE2) is&#x000a0;a trigger of the cardinal signs of inflammation: rubor (erythema), calor (warmth), tumor (swelling), and dolor (pain);&#x000a0;PGE2&#x000a0;increases blood flow and vascular permeability. PGE2 also triggers systemic fever through a hypothalamic-mediated reaction. Sulindac and other NSAIDs are responsible for inhibiting the synthesis of this prostaglandin and others. Sulindac exists as a pro-drug that activates upon initial metabolism.&#x000a0;The metabolism forms sulfide and sulfone derivatives, which inhibit prostaglandin synthesis.<xref ref-type="bibr" rid="article-29677.r5">[5]</xref><xref ref-type="bibr" rid="article-29677.r6">[6]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Sulindac tablets have a similar extent of absorption compared to sulindac solution. Antacids containing aluminum hydroxide 225 mg and magnesium hydroxide 200 mg per 5 mL do not change absorption extent.</p>
        <p><bold>Distribution:</bold>&#x000a0;Sulindac, sulfone, and sulfide metabolites are highly protein-bound (more than 90%), mainly to albumin.&#x000a0;Sulindac can penetrate both the blood-brain barrier and the placental barrier.<xref ref-type="bibr" rid="article-29677.r7">[7]</xref><xref ref-type="bibr" rid="article-29677.r8">[8]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;Sulindac goes through&#x000a0;2 major biotransformations of&#x000a0;the sulfoxide moiety: reduction to the pharmacologically active sulfide metabolite and oxidation to the inactive sulfone metabolite.</p>
        <p><bold>Elimination:</bold>&#x000a0;Approximately half of the administered dose of sulindac is eliminated&#x000a0;by urine with the conjugated sulfone metabolite. Approximately 25% of the administered dose of sulindac is excreted in the feces, the majority as the sulfone or sulfide metabolites. The mean plasma effective half-life for sulindac and its active sulfide metabolite is 7.8 hours and 16.4 hours, respectively.<xref ref-type="bibr" rid="article-29677.r9">[9]</xref></p>
      </sec>
      <sec id="article-29677.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Sulindac is available as 150 mg and 200 mg oral tablets. The maximum recommended daily dosage&#x000a0;is 400 mg. Healthcare providers&#x000a0;recommend administering the lowest effective dose tailored to each patient's needs&#x000a0;for the initial treatment and for the shortest duration possible. Sulindac should be taken with food or milk to decrease gastrointestinal adverse effects.&#x000a0;Clinicians&#x000a0;should carefully consider the potential risks to the benefit of sulindac and other relevant treatment options before use.&#x000a0;</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis:</bold>&#x000a0;The initial recommended dosage of&#x000a0;sulindac is 150 mg twice a day. This dose can be increased or decreased based on the patient's response. The dosage&#x000a0;can be increased up to 400 mg daily. Half of the patient population may expect a prompt response within&#x000a0;1 week of treatment; other patients may require prolonged treatment.<xref ref-type="bibr" rid="article-29677.r10">[10]</xref><xref ref-type="bibr" rid="article-29677.r11">[11]</xref></p>
        <p><bold>Acute supraspinatus tendinitis/subacromial bursitis (acute painful shoulder):</bold>&#x000a0;The initial recommended dosage&#x000a0;of sulindac is&#x000a0;200 mg twice daily. This dose can be increased or decreased based on the therapeutic&#x000a0;response. The dosage can be increased up to 400 mg daily. An&#x000a0;adequate response may be&#x000a0;achieved from 7 to 14 days of therapy.<xref ref-type="bibr" rid="article-29677.r12">[12]</xref></p>
        <p><bold>Acute gouty arthritis:&#x000a0;</bold>The initial recommended dosage of sulindac is&#x000a0;200&#x000a0;mg twice a day. This dose can be increased or decreased based on the&#x000a0;therapeutic&#x000a0;response. The dosage can be increased up to 400 mg daily. An&#x000a0;adequate&#x000a0;response may be&#x000a0;achieved&#x000a0;within&#x000a0;7 days.<xref ref-type="bibr" rid="article-29677.r13">[13]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Use sulindac with caution and monitor treatment in patients with hepatic impairment. Reduction of dose may be needed due to extensive metabolism in the liver.<xref ref-type="bibr" rid="article-29677.r14">[14]</xref></p>
        <p><bold>Renal impairment:&#x000a0;</bold>Patients with impaired renal function should be monitored.&#x000a0;Dose reduction may be needed in patients with advanced renal disease. Dose reduction is recommended for patients with an eGFR of 30 to 60 mL/min/1.73m&#x000b2;.<xref ref-type="bibr" rid="article-29677.r9">[9]</xref>&#x000a0;Discontinuing the treatment is advised&#x000a0;if comorbid&#x000a0;kidney diseases are present. However, use should be avoided for individuals with an eGFR less than 30 mL/min/1.73m&#x000b2;.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>The FDA warns that using NSAIDs, including sulindac, after around 20 weeks of pregnancy may cause fetal renal dysfunction, leading to oligohydramnios and neonatal renal impairment. These effects occur on average after days to weeks of treatment. Oligohydramnios can be reversed upon discontinuation, but it may cause complications such as delayed lung maturation and limb contractures. In cases where NSAIDs are necessary between 20 to 30 weeks of pregnancy, restrict the use to the lowest effective dosage and shortest duration. Avoid administration of NSAIDs at 30 weeks and later due to the additional risk of premature closure of the fetal ductus arteriosus. Consider ultrasound monitoring if treatment extends beyond 48 hours, and discontinue NSAIDs in oligohydramnios.<xref ref-type="bibr" rid="article-29677.r15">[15]</xref></p>
        <p><bold>Breastfeeding&#x000a0;considerations:&#x000a0;</bold>It is unknown if&#x000a0;sulindac&#x000a0;transfers to&#x000a0;breast milk. Some NSAIDs with established safety data and short half-lives&#x000a0;are considered compatible&#x000a0;with lactating patients to treat rheumatic and musculoskeletal diseases. Due to some potential adverse effects of&#x000a0;sulindac&#x000a0;in the breastfeeding infant, the manufacturer recommends discontinuing treatment or breastfeeding based on risk-benefit assessments.<xref ref-type="bibr" rid="article-29677.r16">[16]</xref><xref ref-type="bibr" rid="article-29677.r17">[17]</xref></p>
        <p><bold>Pediatric patients:</bold> The safety and effectiveness of sulindac in pediatric patients have not been established.</p>
        <p><bold>Older patients</bold>: As per the American Geriatric Society 2023 Beers Criteria for potentially inappropriate medication use in older adults, the use of NSAIDs, including sulindac, is associated with an elevated risk of upper gastrointestinal&#x000a0;ulcers, bleeding, or perforation. Complications occur in 1% of individuals undergoing a 3-month to 6-month treatment and 2% to 4% of those subjected to a 1-year treatment duration, with the associated risks gradually increasing over extended periods of use. Additionally, NSAIDs, including sulindac, have the potential to raise blood pressure and induce kidney injury, and these risks are correlated with the dosage.<xref ref-type="bibr" rid="article-29677.r18">[18]</xref></p>
      </sec>
      <sec id="article-29677.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Prostaglandins and thromboxanes have critical functions throughout the body. The wide range of functions results in adverse effects. Blood vessels, the gastrointestinal tract, and kidneys are critical&#x000a0;organ systems impacted by sulindac.</p>
        <list list-type="bullet">
          <list-item>
            <p>Sulindac is commonly&#x000a0;associated with nausea and vomiting, stomach pain, indigestion, diarrhea, constipation, gas, anxiety, dizziness, tinnitus, and urticaria.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The most common&#x000a0;and severe adverse effect of NSAID use involves ulceration of the gastrointestinal&#x000a0;tract, as gastrointestinal&#x000a0;mucosa appears to be protected by prostaglandins. Sulindac is commonly thought to have associations with lower rates of gastrointestinal-related complications when compared to other nonselective NSAIDs; however, the gastrointestinal&#x000a0;adverse effects related to NSAID use appear to be mediated through COX-1, as COX-2 selective NSAIDs are associated with lower risks of gastrointestinal&#x000a0;complications. The simultaneous use of alcohol and or steroids exacerbates adverse effects.<xref ref-type="bibr" rid="article-29677.r19">[19]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sulindac also correlates with renal adverse effects. Certain prostaglandins dilate&#x000a0;the afferent arteriole and may result in a reduced GFR and&#x000a0;increased risk of acute kidney injury. Sulindac and other NSAIDs may also be nephrotoxic and induce renal papillary necrosis and interstitial nephritis. This condition may&#x000a0;be exacerbated with the simultaneous use of other nephrotoxic agents.<xref ref-type="bibr" rid="article-29677.r20">[20]</xref><xref ref-type="bibr" rid="article-29677.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sulindac is associated with various critical adverse effects, including changes in vision, hepatoxicity, pancreatitis, anemia, and Steven-Johnson syndrome.<xref ref-type="bibr" rid="article-29677.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II antagonists:&#x000a0;NSAIDs may attenuate the antihypertensive effects of&#x000a0;ACE inhibitors&#x000a0;and angiotensin II antagonists. This interaction should be considered, particularly in patients concurrently using NSAIDs with ACE inhibitors or angiotensin II antagonists. In patients with compromised renal function, coadministration of NSAIDs with ACE inhibitors or angiotensin II antagonists may exacerbate renal deterioration, leading to reversible acute renal failure. Therefore, regular monitoring of renal function is advised for patients&#x000a0;under combination therapy.<xref ref-type="bibr" rid="article-29677.r23">[23]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Aspirin:&#x000a0;Combining aspirin with sulindac significantly decreases plasma levels of the active sulfide metabolite. In addition, the combination showed that aspirin with sulindac increases gastrointestinal adverse effects.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cyclosporine:&#x000a0;Concomitant use of NSAIDs with cyclosporine may increase cyclosporine-induced toxicity due to reduced renal prostacyclin synthesis. Caution is advised, and renal function should be monitored.<xref ref-type="bibr" rid="article-29677.r24">[24]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diuretics:&#x000a0;Sulindac can diminish the natriuretic effect of furosemide and thiazides in some patients, leading to renal failure. Close observation is recommended during concomitant therapy with NSAIDs.<xref ref-type="bibr" rid="article-29677.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lithium:&#x000a0;NSAIDs may elevate plasma lithium levels and reduce renal lithium clearance, leading to toxicity. Monitoring for signs of lithium toxicity is advised when NSAIDs and lithium are administered concurrently.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Methotrexate: Caution should be exercised when coadministering NSAIDs with methotrexate due to the risk of methotrexate toxicity resulting from methotrexate accumulation.<xref ref-type="bibr" rid="article-29677.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>NSAIDs:&#x000a0;Concomitant use of sulindac with other NSAIDs is not suggested due to an increased risk of gastrointestinal toxicity without a significant increase in efficacy.<xref ref-type="bibr" rid="article-29677.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Oral anticoagulants: Monitoring is recommended when combining sulindac with oral anticoagulants, particularly in patients receiving higher doses or those with renal impairment due to increased bleeding risk.<xref ref-type="bibr" rid="article-29677.r28">[28]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29677.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Per the manufacturer,&#x000a0;a&#x000a0;few absolute contraindications to the use of sulindac are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>The first is a previous hypersensitivity reaction to sulindac or other NSAIDs. NSAID hypersensitivity can present in a variety of ways.<xref ref-type="bibr" rid="article-29677.r21">[21]</xref>&#x000a0;The hypersensitivity&#x000a0;can result in chronic respiratory disease because of the formation of nasal polyps. Cutaneous signs include&#x000a0;urticaria, angioedema,&#x000a0;and generalized anaphylaxis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The other absolute contraindication is in patients in status post coronary artery bypass graft (CABG) operations.</p>
          </list-item>
        </list>
        <p>
<bold>Box Warnings</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>NSAIDs increase the risk of serious and fatal cardiovascular thrombotic events, including stroke and myocardial infarction.&#x000a0;This risk can occur in an early phase of treatment and may increase with the duration of administration.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>NSAIDs increase the risk of serious and fatal gastrointestinal bleeding, ulceration, and perforation of the stomach or intestines.&#x000a0;These adverse events may occur anytime&#x000a0;and without warning. Senior adults are at higher risk of serious gastrointestinal events.<xref ref-type="bibr" rid="article-29677.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sulindac can increase the risk of hypertension or exacerbate existing hypertension.<xref ref-type="bibr" rid="article-29677.r29">[29]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The risk of&#x000a0;hospitalizations for patients with heart failure is increased.<xref ref-type="bibr" rid="article-29677.r30">[30]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cholestatic hepatitis cases are reported in some patients. Therefore, if abnormal liver tests persist or worsen, clinical signs and symptoms consistent with liver disease develop, or systemic manifestations occur (eg, eosinophilia and rash), and sulindac should be discontinued.<xref ref-type="bibr" rid="article-29677.r31">[31]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic use of NSAIDs is linked with renal papillary necrosis and other renal injuries. Therefore, caution&#x000a0;is recommended in patients with heart failure, impaired renal function, liver dysfunction, volume-depleted patients, those&#x000a0;prescribed diuretics and ACE inhibitors, and older patients.<xref ref-type="bibr" rid="article-29677.r29">[29]</xref><xref ref-type="bibr" rid="article-29677.r32">[32]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)&#x000a0;is observed in patients&#x000a0;administered sulindac, so use is discontinued if any signs or symptoms of DRESS develop.<xref ref-type="bibr" rid="article-29677.r33">[33]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29677.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Sulindac use, as is the case with other NSAIDs, does not involve routine monitoring. No regular blood work is necessary; however, sulindac is not free from toxic adverse drug reactions. Adhering to the dosing regimen is critical in preventing&#x000a0;some of the abovementioned adverse effects.<xref ref-type="bibr" rid="article-29677.r34">[34]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Clinicians should check hemoglobin or hematocrit if a patient develops any&#x000a0;signs or symptoms of anemia.<xref ref-type="bibr" rid="article-29677.r35">[35]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If pancreatitis develops, monitor closely with appropriate laboratory studies (lipase, serum, and urine amylase, amylase/creatinine clearance ratio, electrolytes, serum calcium, and glucose)<xref ref-type="bibr" rid="article-29677.r36">[36]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with hepatic impairment need&#x000a0;close monitoring.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pregnant women who use sulindac for more than 48 hours between 2&#x000a0;and 30 weeks of gestation should be monitored for oligohydramnios.<xref ref-type="bibr" rid="article-29677.r37">[37]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients on long-term treatment should have CBC and chemistry profiles checked periodically since sulindac might cause unexpected severe gastrointestinal bleeding and ulcerations.<xref ref-type="bibr" rid="article-29677.r38">[38]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29677.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Sulindac toxicity is rare; few cases are reported in the literature. Though sulindac is an NSAID, the toxicity&#x000a0;does not present similarly to&#x000a0;salicylate (aspirin) toxicity&#x000a0;with metabolic acidosis, respiratory alkalosis, and tinnitus. Cases in the literature have demonstrated hepatic and renal toxicity associated with sulindac overdose; a case of granulocytosis&#x000a0;is secondary to sulindac toxicity. One of the cases with hepatorenal toxicity further resulted in ischemic skin changes and ulceration.<xref ref-type="bibr" rid="article-29677.r39">[39]</xref><xref ref-type="bibr" rid="article-29677.r40">[40]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Since exceedingly few cases of sulindac toxicity&#x000a0;are reported, many implications of overdose have not&#x000a0;been&#x000a0;investigated. Other research has demonstrated the utility of activated charcoal in the acute treatment of sulindac toxicity. Charcoal can help minimize absorption and some of the later sequelae associated with the drug's toxicity. However, other studies have demonstrated that once the drug&#x000a0;is in the system, proper treatment protocol involves supportive care, which includes aggressive hydration, fluid replacement, and hemodialysis in some instances.<xref ref-type="bibr" rid="article-29677.r39">[39]</xref></p>
      </sec>
      <sec id="article-29677.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>NSAIDs such as sulindac are frequently prescribed for patients with arthritis, spondylitis, and tendinitis. Nurses should have a comprehensive understanding of the signs and symptoms of potential toxicities and should provide thorough counseling to patients regarding the importance of adhering to scheduled dosing regimens. Pharmacists should meticulously check the dosage, confirm the suitability of sulindac treatment, and promptly communicate any concerns to the clinicians.</p>
        <p>A study was conducted to assess the influence of medication reviews and pharmacist counseling on NSAID utilization among individuals aged 60 and older. The findings revealed that among the 83 participants, a significant proportion (47.6%) reported NSAID usage, with 71.8% exhibiting inappropriate use. Following counseling, post-intervention follow-up indicated a positive impact, with the proportion of appropriate users increasing to 51.3% and inappropriate users decreasing to 48.7%. Notably, participants reported enhanced comprehension of NSAID-related risks, and 55.6% of those in the study reported engaging in more meaningful discussions with clinicians.</p>
        <p>The findings suggest that pharmacist counseling can be pivotal in mitigating potentially inappropriate NSAID use and enhancing risk awareness among older adults.<xref ref-type="bibr" rid="article-29677.r41">[41]</xref>&#x000a0;An&#x000a0;interprofessional healthcare team, including clinicians, specialists, specialty-trained nurses, and pharmacists collaborating across disciplines, can work together to attain optimal patient outcomes concerning sulindac therapy.</p>
      </sec>
      <sec id="article-29677.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29677&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29677">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29677/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29677">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29677.s11">
        <title>References</title>
        <ref id="article-29677.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karachalios</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Donas</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Sulindac in the treatment of acute gout arthritis.</article-title>
            <source>Int J Tissue React</source>
            <year>1982</year>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>297</fpage>
            <page-range>297-9</page-range>
            <pub-id pub-id-type="pmid">7169301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurpinar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grizzle</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Piazza</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs.</article-title>
            <source>Front Oncol</source>
            <year>2013</year>
            <volume>3</volume>
            <fpage>181</fpage>
            <pub-id pub-id-type="pmid">23875171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herzig</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hardiman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weiser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Paquette</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Feingold</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Steele</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Polyposis Syndromes.</article-title>
            <source>Dis Colon Rectum</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>60</volume>
            <issue>9</issue>
            <fpage>881</fpage>
            <page-range>881-894</page-range>
            <pub-id pub-id-type="pmid">28796726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Saad</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Nonsteroidal Anti-Inflammatory Drugs Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30252262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator.</article-title>
            <source>Sci Rep</source>
            <year>2016</year>
            <month>Jan</month>
            <day>18</day>
            <volume>6</volume>
            <fpage>19534</fpage>
            <pub-id pub-id-type="pmid">26777116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strong</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Warner</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Renwick</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Sulindac metabolism: the importance of an intact colon.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1985</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>387</fpage>
            <page-range>387-93</page-range>
            <pub-id pub-id-type="pmid">4042521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lampela</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Nuutinen</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Ala-Kokko</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Parikka</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Laitinen</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Jouppila</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>V&#x000e4;h&#x000e4;kangas</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Placental transfer of sulindac, sulindac sulfide, and indomethacin in a human placental perfusion model.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>180</volume>
            <issue>1 Pt 1</issue>
            <fpage>174</fpage>
            <page-range>174-80</page-range>
            <pub-id pub-id-type="pmid">9914600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Modi</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Prentice</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Sulindac for stroke treatment: neuroprotective mechanism and therapy.</article-title>
            <source>Neural Regen Res</source>
            <year>2014</year>
            <month>Dec</month>
            <day>01</day>
            <volume>9</volume>
            <issue>23</issue>
            <fpage>2023</fpage>
            <page-range>2023-5</page-range>
            <pub-id pub-id-type="pmid">25657710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perazella</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>NSAIDs in CKD: Are They Safe?</article-title>
            <source>Am J Kidney Dis</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>76</volume>
            <issue>4</issue>
            <fpage>546</fpage>
            <page-range>546-557</page-range>
            <pub-id pub-id-type="pmid">32479922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hearron</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Double-blind comparison of flurbiprofen and sulindac for the treatment of osteoarthritis.</article-title>
            <source>Am J Med</source>
            <year>1986</year>
            <month>Mar</month>
            <day>24</day>
            <volume>80</volume>
            <issue>3A</issue>
            <fpage>112</fpage>
            <page-range>112-7</page-range>
            <pub-id pub-id-type="pmid">3515919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sitar</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>MacDougall</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mitenko</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1985</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>228</fpage>
            <page-range>228-34</page-range>
            <pub-id pub-id-type="pmid">4017423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegmeth</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sieberer</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>[Sulindac in the treatment of soft tissue rheumatism (periarthropathy of the hip and shoulder (author's transl)].</article-title>
            <source>Wien Med Wochenschr</source>
            <year>1980</year>
            <month>Jul</month>
            <day>31</day>
            <volume>130</volume>
            <issue>13-14</issue>
            <fpage>492</fpage>
            <page-range>492-5</page-range>
            <pub-id pub-id-type="pmid">7424040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Gout Medications</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>7</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">31643551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <chapter-title>Sulindac</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>3</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">31643638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dathe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hultzsch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pritchard</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>75</volume>
            <issue>10</issue>
            <fpage>1347</fpage>
            <page-range>1347-1353</page-range>
            <pub-id pub-id-type="pmid">31273431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sammaritano</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Bermas</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Chakravarty</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clowse</surname>
                <given-names>MEB</given-names>
              </name>
              <name>
                <surname>Lockshin</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Marder</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Branch</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Buyon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Christopher-Stine</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Crow-Hercher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cush</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Druzin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laskin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Plante</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salmon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Simard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Somers</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Steen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tedeschi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Vinet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Yazdany</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barbhaiya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bettendorf</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Eudy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jayatilleke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tarter</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Birru Talabi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D'Anci</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>529</fpage>
            <page-range>529-556</page-range>
            <pub-id pub-id-type="pmid">32090480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vickers</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Landau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reece-Stremtan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>ABM Clinical Protocol #28, Peripartum Analgesia and Anesthesia for the Breastfeeding Mother.</article-title>
            <source>Breastfeed Med</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>164</fpage>
            <page-range>164-171</page-range>
            <pub-id pub-id-type="pmid">29595994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bjorkman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and esophagus.</article-title>
            <source>Am J Med</source>
            <year>1998</year>
            <month>Nov</month>
            <day>02</day>
            <volume>105</volume>
            <issue>5A</issue>
            <fpage>17S</fpage>
            <page-range>17S-21S</page-range>
            <pub-id pub-id-type="pmid">9855171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wongrakpanich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wongrakpanich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Melhado</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rangaswami</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly.</article-title>
            <source>Aging Dis</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>143</fpage>
            <page-range>143-150</page-range>
            <pub-id pub-id-type="pmid">29392089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e1;nchez-Borges</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caballero-Fonseca</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Capriles-Hulett</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Aveledo</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs: An Update.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2010</year>
            <month>Jan</month>
            <day>05</day>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-18</page-range>
            <pub-id pub-id-type="pmid">27713240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mockenhaupt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>RS</given-names>
              </name>
              <collab>SCAR Study Group</collab>
            </person-group>
            <article-title>The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective.</article-title>
            <source>J Rheumatol</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>10</issue>
            <fpage>2234</fpage>
            <page-range>2234-40</page-range>
            <pub-id pub-id-type="pmid">14528522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camin</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Cols</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chevarria</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Osuna</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Carreras</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lisbona</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Coderch</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Acute kidney injury secondary to a combination of renin-angiotensin system inhibitors, diuretics and NSAIDS: "The Triple Whammy".</article-title>
            <source>Nefrologia</source>
            <year>2015</year>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-206</page-range>
            <pub-id pub-id-type="pmid">26300514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Yazbi</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Eid</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>El-Mas</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular and renal interactions between cyclosporine and NSAIDs: Underlying mechanisms and clinical relevance.</article-title>
            <source>Pharmacol Res</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>129</volume>
            <fpage>251</fpage>
            <page-range>251-261</page-range>
            <pub-id pub-id-type="pmid">29183768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lapi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Azoulay</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nessim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Suissa</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study.</article-title>
            <source>BMJ</source>
            <year>2013</year>
            <month>Jan</month>
            <day>08</day>
            <volume>346</volume>
            <fpage>e8525</fpage>
            <pub-id pub-id-type="pmid">23299844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uwai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Inui</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2000</year>
            <month>Dec</month>
            <day>01</day>
            <volume>409</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-6</page-range>
            <pub-id pub-id-type="pmid">11099697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clinard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sgro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bardou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hillon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dumas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kreft-Jais</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Escousse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bonithon-Kopp</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>279</fpage>
            <page-range>279-83</page-range>
            <pub-id pub-id-type="pmid">15103437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villa Zapata</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hansten</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Panic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Gephart</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Subbian</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malone</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis.</article-title>
            <source>Thromb Haemost</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>120</volume>
            <issue>7</issue>
            <fpage>1066</fpage>
            <page-range>1066-1074</page-range>
            <pub-id pub-id-type="pmid">32455439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ungprasert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cheungpasitporn</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies.</article-title>
            <source>Eur J Intern Med</source>
            <year>2015</year>
            <month>May</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>285</fpage>
            <page-range>285-91</page-range>
            <pub-id pub-id-type="pmid">25862494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eriksson</surname>
                <given-names>LO</given-names>
              </name>
              <name>
                <surname>Beermann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kallner</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Renal function and tubular transport effects of sulindac and naproxen in chronic heart failure.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>646</fpage>
            <page-range>646-54</page-range>
            <pub-id pub-id-type="pmid">3319349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wood</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Mundo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Searle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>LW</given-names>
              </name>
            </person-group>
            <article-title>Sulindac hepatotoxicity: effects of acute and chronic exposure.</article-title>
            <source>Aust N Z J Med</source>
            <year>1985</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>397</fpage>
            <page-range>397-401</page-range>
            <pub-id pub-id-type="pmid">3866535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murray</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Brater</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Renal toxicity of the nonsteroidal anti-inflammatory drugs.</article-title>
            <source>Annu Rev Pharmacol Toxicol</source>
            <year>1993</year>
            <volume>33</volume>
            <fpage>435</fpage>
            <page-range>435-65</page-range>
            <pub-id pub-id-type="pmid">8494347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goodwin</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Glenny</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports.</article-title>
            <source>Arch Intern Med</source>
            <year>1992</year>
            <month>Jul</month>
            <volume>152</volume>
            <issue>7</issue>
            <fpage>1521</fpage>
            <page-range>1521-4</page-range>
            <pub-id pub-id-type="pmid">1627033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lione</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scialli</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>The developmental toxicity of indomethacin and sulindac.</article-title>
            <source>Reprod Toxicol</source>
            <year>1995</year>
            <season>Jan-Feb</season>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-20</page-range>
            <pub-id pub-id-type="pmid">8520134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angeles</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Yacob</surname>
                <given-names>UA</given-names>
              </name>
              <name>
                <surname>Cash</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Fetten</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Sulindac-induced immune hemolytic anemia.</article-title>
            <source>Transfusion</source>
            <year>1994</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>255</fpage>
            <page-range>255-8</page-range>
            <pub-id pub-id-type="pmid">8146901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Memon</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>Pancreatitis and sulindac.</article-title>
            <source>Ann Intern Med</source>
            <year>1982</year>
            <month>Jul</month>
            <volume>97</volume>
            <issue>1</issue>
            <fpage>139</fpage>
            <pub-id pub-id-type="pmid">7091990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schoenfeld</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bar</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Merlob</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovadia</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>NSAIDs: maternal and fetal considerations.</article-title>
            <source>Am J Reprod Immunol</source>
            <year>1992</year>
            <season>Oct-Dec</season>
            <volume>28</volume>
            <issue>3-4</issue>
            <fpage>141</fpage>
            <page-range>141-7</page-range>
            <pub-id pub-id-type="pmid">1285865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lapane</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Spooner</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mucha</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Straus</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2001</year>
            <month>May</month>
            <volume>49</volume>
            <issue>5</issue>
            <fpage>577</fpage>
            <page-range>577-84</page-range>
            <pub-id pub-id-type="pmid">11380750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaughn</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Ghossein</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Kirkpatrick</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Acute kidney injury, hyperbilirubinemia, and ischemic skin necrosis due to massive sulindac overdose.</article-title>
            <source>Curr Drug Saf</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-2</page-range>
            <pub-id pub-id-type="pmid">25986039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gross</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Granulocytosis and a sulindac overdose.</article-title>
            <source>Ann Intern Med</source>
            <year>1982</year>
            <month>Jun</month>
            <volume>96</volume>
            <issue>6 Pt 1</issue>
            <fpage>793</fpage>
            <page-range>793-4</page-range>
            <pub-id pub-id-type="pmid">7091952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29677.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bear</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pharmacist Counseling and the Use of Nonsteroidal Anti-Inflammatory Drugs by Older Adults.</article-title>
            <source>Consult Pharm</source>
            <year>2017</year>
            <month>Mar</month>
            <day>01</day>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-168</page-range>
            <pub-id pub-id-type="pmid">28270271</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
